<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03332576</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-DPX-Survivac-03</org_study_id>
    <nct_id>NCT03332576</nct_id>
  </id_info>
  <brief_title>Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer</brief_title>
  <official_title>Phase 1b Study of Extended Dosing of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoVaccine Technologies, Inc. (IMV Inc.)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunoVaccine Technologies, Inc. (IMV Inc.)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As a follow-on study to NCT01416038, this study is designed to identify the optimal dosage of&#xD;
      immunotherapeutic survivin vaccine DPX-Survivac and low dose oral cyclophosphamide. The&#xD;
      combination treatment is being evaluated in a non-randomized, multi-cohort study as&#xD;
      post-chemotherapy treatment for patients with late-stage ovarian, fallopian tube, or&#xD;
      peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 23, 2013</start_date>
  <completion_date type="Actual">September 9, 2019</completion_date>
  <primary_completion_date type="Actual">September 8, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by adverse event reporting (CTCAE)</measure>
    <time_frame>up to 11 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cell mediated immunity as measured by the antigen specific response in peripheral blood</measure>
    <time_frame>up to 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact on residual tumour</measure>
    <time_frame>up to 11 months</time_frame>
    <description>Evaluated by standard of care radiology and CA-125</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Peritoneal Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Doses DPX-Survivac (2 prime q3w, 4 boost q8w)&#xD;
Low dose cyclophosphamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Doses DPX-Survivac (2 prime q3w, 4 boost q8w)&#xD;
Low dose cyclophosphamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 Doses DPX-Survivac (1 prime, 2 boost q8w)&#xD;
Low dose cyclophosphamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 Doses DPX-Survivac (2 prime q6w, 3 boost q6w)&#xD;
Low dose cyclophosphamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 Doses DPX-Survivac/DPX-Survivac(Aqueous) (2 prime q4w, 3 boost q4w)&#xD;
Low dose cyclophosphamide</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DPX-Survivac</intervention_name>
    <description>SubQ injection</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DPX-Survivac(Aqueous)</intervention_name>
    <description>SubQ injection</description>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>PO BID</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed stage IIc-IV epithelial ovarian, fallopian tube or peritoneal&#xD;
             cancer&#xD;
&#xD;
          -  Complete or partial response following standard of care surgery and first line&#xD;
             chemotherapy&#xD;
&#xD;
          -  May have one disease recurrence with complete or partial response or stable disease&#xD;
             following standard of care second line care treatment&#xD;
&#xD;
          -  Previous investigational biologic therapy allowed, must be more than 56 days prior to&#xD;
             first injection&#xD;
&#xD;
          -  Previous treatment with bisphosphonate allowed, must be completed 14 days prior to&#xD;
             first injection&#xD;
&#xD;
          -  Ambulatory with an ECOG 0-1&#xD;
&#xD;
          -  Life expectancy &gt; 6 months&#xD;
&#xD;
          -  Meet protocol-specified lab requirements&#xD;
&#xD;
          -  Provide informed consent and have ability to comply with protocol requirements&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent chemotherapy, radiation therapy, immunotherapy are excluded (washout&#xD;
             periods as specified in protocol)&#xD;
&#xD;
          -  Prior receipt of survivin based vaccines&#xD;
&#xD;
          -  Participation in prior therapeutic adjuvant ovarian cancer studies, except for&#xD;
             platinum-based adjuvant studies&#xD;
&#xD;
          -  Progressive disease (rising CA-125 acceptable)&#xD;
&#xD;
          -  More than one course of chemotherapy for recurrent disease&#xD;
&#xD;
          -  Concurrent bevacizumab as maintenance therapy&#xD;
&#xD;
          -  Concurrent second malignancy other than non-melanoma skin cancer, cervical carcinoma&#xD;
             in situ, or controlled bladder cancer&#xD;
&#xD;
          -  History of autoimmune disease&#xD;
&#xD;
          -  Recent history of thyroiditis&#xD;
&#xD;
          -  Presence of a serious acute infection or chronic infection&#xD;
&#xD;
          -  Brain metastases&#xD;
&#xD;
          -  Other serious intercurrent chronic or acute illness&#xD;
&#xD;
          -  Ongoing treatment with steroid therapy or other immunosuppressive&#xD;
&#xD;
          -  Acute or chronic skin disorders&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenox Hill Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 2, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vaccine</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>combination therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

